New York

Bristol Myers “dual immunotherapy” beats Opdivo alone in melanoma study

Bristol Myers Squibb reported Phase 3 data that show its experimental cancer immunotherapy relatlimab, combined with the company’s blockbuster drug Opdivo, was better at stopping melanoma from progressing. BMS will present the data at the upcoming annual meeting of the American Society of Clinical Oncology.

Health analytics startup Komodo passes $3.3B valuation

  • by

Komodo, a data analytics startup building out information on patient encounters and outcomes, raised $220 million in funding. It plans to use the funds to build out its platform and further integrate it in users’ workflows.

Care coordination startup Unite Us raises $150M

  • by

Unite Us, a New York-based technology company that makes coordination of care software, passed a $1.6 billion valuation. It build networks with local providers and works to connect members with community resources.

Sorting Out How Politics, Policies Figure in Flap Over New York Nursing Home Covid Death Rates

  • by

The plaudits have faded for New York Gov. Andrew Cuomo. Once hailed as a paragon of pandemic governing, he’s since come under scorching criticism for undercounting the state’s covid deaths among nursing home residents by as much as half. The tallying flap drew attention to… Read More »Sorting Out How Politics, Policies Figure in Flap Over New York Nursing Home Covid Death Rates

4 takeaways from Teladoc’s earnings

  • by

After a year of record growth, Teladoc set expectations for limited growth in its paid memberships and visits in 2021. But the company still sees long-term opportunities with a primary care pilot it is launching and its acquisition of Livongo.

Oscar Health looks to raise $1B in IPO

  • by

Insurance startup Oscar Health plans to price its IPO between $32 and $34 per share.  The New York-based startup plans to trade on the New York Stock Exchange under the ticker “OSCR.”

Startup banks on immune-system memory to tackle cancer

  • by

Loki Therapeutics is advancing research that leverages the immune system’s ability to recall childhood vaccinations and direct it against cancer. The company’s lead therapy candidate could enter phase 1 clinical trials this year.

INVEST Precision Medicine Pitch Perfect winner spotlight: TrialSpark

  • by

Judges picked TrialSpark as the winner on the life sciences track of the pitch competition at MedCity’s virtual precision medicine conference. While the company is focused on improving clinical trials for others, it hopes eventually to bring drugs of its own to market.

Molina buys another Medicaid plan for $380M

  • by

Molina announced it will acquire the assets of Affinity Health Plan, a New York-based Medicaid managed care organization. It’s one of several Medicaid MCO purchases the insurer has announced this year.

Pfizer, BioNTech start late-stage study of Covid-19 vaccine

  • by

The companies said they had started a Phase II/III trial BNT162b2. The news comes the day after Moderna announced the launch of its Phase III study and days after Pfizer and BioNTech signed a nearly $2 billion vaccine supply deal with the federal government.

MedCity Pivot Podcast: An interview with Bari Kowal, vice president of global clinical operations, Regeneron

Bari Kowal, vice president of global clinical operations at Regeneron Pharmaceuticals, gives an update on the clinical trials ongoing to develop drugs to fight Covid-19 and provides insights on how the clinical trials landscape and pharma overall must change in the next episode of MedCity… Read More »MedCity Pivot Podcast: An interview with Bari Kowal, vice president of global clinical operations, Regeneron

BARDA, DoD give Regeneron $450M contract for Covid-19 antiviral drug

The contract covers manufacture and supply of the two-antibody drug cocktail REGN-COV2. The company had announced Monday that it entered the drug into three late-stage clinical studies, both as a treatment for existing SARS-CoV-2 infections and a preventive treatment for healthy exposed people.